Related Experiment Video
Updated: May 17, 2026
A Reproducible Cartilage Impact Model to Generate Post-Traumatic Osteoarthritis in the Rabbit
Published on: November 21, 2023
Stigmasterol blocks cartilage degradation in rabbit model of osteoarthritis
Wei-Ping Chen1, Chong Yu, Peng-Fei Hu
1Department of Orthopedics Surgery, the 2nd Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, People's Republic of China.
Abstract:
Stigmasterol has been shown exhibit anti-osteoarthritic properties in vitro studies. However, the in vivo effects of stigmasterol on cartilage are still unclear. This study investigated the anti-osteoarthritic properties of stigmasterol on cartilage degradation in a rabbit model of osteoarthritis (OA). Twenty rabbits underwent bilateral anterior cruciate ligament transection (ACLT) to induce OA. Five rabbits were used as normal control. Two weeks after operation, the rabbits were randomly divided into two groups. Each group of 10 rabbits received intra-articular injection with 0.3 ml of stigmasterol in left knees and vehicle in right knees, once weekly. Group 1 was killed 6 weeks after ACLT and 2 were sacrificed 9 weeks after ACLT. The knee joints were assessed by gross morphology, histology and gene expression analysis. We found that expression of genes encoding matrix metalloproteinases (MMPs) was significantly higher while tissue inhibitors of metalloproteinase (TIMP)-1 was significantly lower in the both joints of the two OA groups compared to normal controls. Stigmasterol reduced the cartilage degradation as assessed by histological analysis and markedly suppressed MMPs expression both in group 1 and group 2. Our results suggest that stigmasterol may be considered as a possible therapeutical agent in the treatment of OA.
Insights
Stigmasterol shows promise in treating osteoarthritis (OA). This study found that stigmasterol reduced cartilage degradation and suppressed matrix metalloproteinases in a rabbit OA model.
Area of Science:
- Biochemistry
- Orthopedics
- Pharmacology
Background:
- In vitro studies suggest stigmasterol possesses anti-osteoarthritic properties.
- The in vivo efficacy of stigmasterol on cartilage in osteoarthritis (OA) remains largely uninvestigated.
Purpose of the Study:
- To evaluate the in vivo anti-osteoarthritic effects of stigmasterol on cartilage degradation.
- To investigate the impact of stigmasterol on matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMP)-1 in an experimental OA model.
Main Methods:
- Osteoarthritis was induced in rabbits via anterior cruciate ligament transection (ACLT).
- Rabbits received intra-articular injections of stigmasterol or vehicle weekly.
- Knee joints were analyzed using gross morphology, histology, and gene expression analysis at 6 and 9 weeks post-ACLT.
Main Results:
- Osteoarthritic rabbits exhibited significantly higher MMP gene expression and lower TIMP-1 expression compared to controls.
- Stigmasterol treatment significantly reduced cartilage degradation as determined by histological assessment.
- Stigmasterol markedly suppressed MMP expression in the affected joints.
Conclusions:
- Stigmasterol demonstrates significant in vivo anti-osteoarthritic properties.
- Stigmasterol may serve as a potential therapeutic agent for osteoarthritis treatment by modulating cartilage degradation and MMP activity.
